MedImmune LLC
Quick facts
Marketed products
- Bivalent influenza vaccine
- FluMist Quadrivalent (2017-2018) · Immunology
FluMist Quadrivalent is a live attenuated influenza vaccine that stimulates an immune response in the nasal passages to prevent influenza infection. - FluMist trivalent (2015-2016) · Immunology
FluMist is a live attenuated influenza vaccine that stimulates immune response by delivering weakened flu virus strains intranasally. - ICE · Immunology
ICE is an intracellular caspase inhibitor that blocks apoptosis by inhibiting caspase enzymes responsible for programmed cell death. - Liquid Palivizumab · Immunology / Infectious Disease
Palivizumab is a monoclonal antibody that binds to the fusion (F) protein on the surface of respiratory syncytial virus (RSV), preventing viral attachment and entry into host cells. - Lyophilized Palivizumab
- Monovalent Frozen FluMist®
- Monovalent Influenza Vaccine
- Monovalent influenza virus vaccine
- Trivalent Influenza Vaccine · Immunology
The trivalent influenza vaccine stimulates the immune system to produce antibodies against three strains of influenza virus, providing protection against seasonal flu infection. - Trivalent Influenza Virus Vaccine
Phase 3 pipeline
- AV024 · Immunology
AV024 is a monoclonal antibody that targets and inhibits IL-6 signaling to reduce inflammatory responses. - CAIV-T · Immunology / Infectious Disease
CAIV-T is a live attenuated influenza vaccine administered intranasally that stimulates mucosal and systemic immune responses against influenza A and B viruses. - CAIV-T and TIV · Immunology / Infectious Disease
CAIV-T is a live attenuated influenza vaccine administered intranasally, while TIV is a trivalent inactivated influenza vaccine, both designed to induce immune responses against seasonal influenza strains. - CAIV-T, Liquid · Immunology
CAIV-T is a live attenuated influenza vaccine administered as a nasal spray that stimulates mucosal and systemic immune responses against influenza. - CAIV-T or TIV · Immunology / Infectious Disease
CAIV-T is a live attenuated influenza vaccine administered intranasally that stimulates mucosal and systemic immune responses against influenza A and B viruses. - CAIVT · Immunology / Infectious Disease
CAIVT is a live attenuated influenza vaccine designed to provide broad protection against multiple influenza virus strains through intranasal delivery. - Dapaglifozin · Metabolic
- FluMist/B/Victoria · Immunology / Infectious Disease
FluMist is a live attenuated influenza vaccine that stimulates immune response by delivering weakened influenza virus strains intranasally. - FluMist/B/Yamagata · Immunology
FluMist is a live attenuated influenza vaccine that stimulates immune response by delivering weakened influenza virus strains intranasally. - Liquid CAIV-T · Immunology / Infectious Disease
Liquid CAIV-T is a live attenuated influenza vaccine administered intranasally that stimulates mucosal and systemic immune responses against influenza A and B viruses. - MEDI-546 · Immunology
MEDI-546 is a monoclonal antibody that targets and inhibits B-cell activating factor (BAFF) to reduce B-cell proliferation and autoimmune responses. - MEDI4736 · Oncology
MEDI4736 is a monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and PD-L2 receptors to enhance anti-tumor immune responses. - MEDI8897 · Immunology / Infectious Disease
MEDI8897 is a monoclonal antibody that provides extended half-life neutralization of respiratory syncytial virus (RSV) through engineered Fc region modifications. - motavizumab (MEDI-524) · Respiratory
Motavizumab is a monoclonal antibody that targets the respiratory syncytial virus (RSV) F-protein. - Q/LAIV-BFS (MEDI8662) · Immunology / Infectious Disease
Q/LAIV-BFS is a quadrivalent live attenuated influenza vaccine formulated in a pre-filled, single-dose applicator for intranasal administration. - Q/LAIV (MEDI3250) · Immunology / Infectious Disease
Q/LAIV is a live attenuated influenza vaccine (LAIV) engineered with a reassortant backbone to provide broad protection against seasonal influenza strains.
Phase 2 pipeline
- CAIV-T 10^7 · Infectious Disease
CAIV-T 10^7 is a live attenuated influenza vaccine. - CAIVT 10^5 · Respiratory
CAIVT 10^5 is a live attenuated virus vaccine. - FluMist, Influenza Virus Vaccine Live · Immunology
FluMist is a live attenuated influenza vaccine that replicates in the nasal mucosa to stimulate local and systemic immune responses against influenza viruses. - Frozen FluMist®
- MEDI-493
- MEDI--522
- MEDI-534
- MEDI-545
- MEDI-551
- MEDI-573
- MEDI0382
- MEDI3902
- MEDI4893
- MEDI5884
- MEDI6012 IV Push
- Motavizumab, palivizumab
- Paclitaxel or Nab-Paclitaxel
- Palivizumab, motavizumab
- Tralokinumab 300 mg, Q2W
Phase 1 pipeline
- ACP-501
- CAT 354
- IPH5201
- MEDI-4166
- MEDI 517
- Medi-524
- MEDI-551 100 MG-IV
- MEDI-551 30 MG-IV
- MEDI-551 300 MG-SC
- MEDI-551 60 MG-SC
- MEDI-551 600 MG-IV
- MEDI-559
- MEDI-563
- MEDI0639
- MEDI0680
- MEDI1191
- MEDI1873
- MEDI2338
- MEDI3726 & Enzalutamide Combo
- MEDI3726 Post-Chemo
- MEDI3726 Pre-Chemo
- MEDI3902 - Dose 1
- MEDI4276
- MEDI4736 Evaluate MEDI4736 in MDS
- MEDI5083 monotherapy
- Medi5083 with Durvalumab and Docetaxel
- MEDI5395
- MEDI6383
- MEDI6383 and MEDI4736
- MEDI7247
- MEDI7836 Dose 1
- MEDI8897 50 mg
- MEDI8897 Intramuscular
- MEDI8897 Intravenous
- MEDI9090
- MEDI9314
- MEID5083 with Durvalumab or Tremelimumab
- RSV sF 50 mcg
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: